Under the agreement, Cipla now has the sole right to market, distribute and sell the cough syrup Corex Dx and Corex LS, the non-steroidal anti-inflammatory drug (NSAID) Dolonex, the proton pump inhibitor (PPI) Neksium and the oral antibiotic Dalacin C in India.